Speciality Medicines Ltd.
BBSE:SPML149.00
INR
-7.95
(-5.07%)
ISIN
INE0R0M01014
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Parthkumar Babulal Goyani
- Full Time Employees
- 25
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Mumbai India
- IPO Date
- Mar 30, 2026
- Website
- specialitymedicine.com
- Similar Companies
- Business
- Speciality Medicines Ltd. is an India-based pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of finished pharmaceutical formulations, active pharmaceutical ingredients (APIs), and healthcare products. The company operates across multiple therapeutic segments and offers a comprehensive portfolio of finished dosage forms and healthcare solutions, including oral solid dosages such as tablets and capsules; liquid formulations comprising syrups, suspensions, and oral drops; topical preparations including ointments, creams, and gels; sterile injectables and infusions; bulk pharmaceutical chemicals and drug intermediates; and dietary supplements, vitamins, and nutraceutical formulations. Its key therapeutic focus areas encompass anti-infectives, analgesics, antipyretics, gastrointestinal agents, cardiovascular medicines, anti-diabetic therapies, dermatological products, and respiratory treatments. Speciality Medicines Ltd. supplies its products to a broad client base that includes institutional hospitals, government healthcare programs, retail pharmacy chains, independent medical practitioners, and wholesale distributors. Geographically, the company maintains extensive domestic distribution across India while exporting select generic formulations and bulk drugs to emerging markets across Asia and Africa. Founded in 1993 and headquartered in Mumbai, Maharashtra, India, the company maintains manufacturing facilities compliant with Good Manufacturing Practice (GMP) guidelines. In recent corporate developments, Speciality Medicines Ltd. has executed key strategic initiatives, including upgrading and expanding its formulation manufacturing infrastructure to comply with revised Schedule M and updated regulatory standards; introducing new product lines in high-demand chronic therapy and preventative nutraceutical categories; entering into strategic third-party contract manufacturing alliances and co-distribution partnerships to enhance market penetration; and implementing operational reorganizations to streamline inventory management, procurement, and regional supply chain logistics.